Neurogene Inc. (NGNE)
- Previous Close
15.59 - Open
15.48 - Bid 19.98 x 300
- Ask 20.58 x 200
- Day's Range
15.48 - 20.93 - 52 Week Range
12.49 - 74.49 - Volume
1,057,188 - Avg. Volume
251,312 - Market Cap (intraday)
301.55M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-4.09 - Earnings Date Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
55.60
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
www.neurogene.comRecent News: NGNE
View More
Performance Overview: NGNE
Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NGNE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NGNE
View MoreValuation Measures
Market Cap
231.59M
Enterprise Value
107.13M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
219.29
Price/Book (mrq)
1.69
Enterprise Value/Revenue
115.81
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.36%
Return on Equity (ttm)
-41.34%
Revenue (ttm)
925k
Net Income Avi to Common (ttm)
2.36M
Diluted EPS (ttm)
-4.09
Balance Sheet and Cash Flow
Total Cash (mrq)
153.9M
Total Debt/Equity (mrq)
8.89%
Levered Free Cash Flow (ttm)
-34.07M
Research Analysis: NGNE
View MoreCompany Insights: NGNE
NGNE does not have Company Insights